Postpartum remodeling, lactation, and breast cancer risk: Summary of a national cancer institute-sponsored workshop

Journal of the National Cancer Institute

Volumn 105, Issue 3, 2013, Pages 166-174

  Faupel Badger, Jessica M ^a   Arcaro, Kathleen F ^b   Balkam, Jane J ^c   Heather Eliassen, A ^d   Hassiotou, Foteini ^e   Lebrilla, Carlito B ^f   Michels, Karin B ^d,g   Palmer, Julie R ^h   Schedin, Pepper ⁱ   Stuebe, Alison M ^j   Watson, Christine J ^k   Sherman, Mark E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c NOTRE DAME OF MARYLAND UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h BOSTON UNIVERSITY   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BRCA1 PROTEIN; BRCA2 PROTEIN; COLLAGEN; CYCLOOXYGENASE 2; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE; PROLACTIN; STAT3 PROTEIN;

BLOOD LEVEL; BREAST CANCER; BREAST CARCINOGENESIS; BREAST DUCT; BREAST FEEDING; BREAST MILK; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CELLULAR DISTRIBUTION; CYTOLYSIS; DNA METHYLATION; HUMAN; LACTATION; LOW DRUG DOSE; MAMMARY GLAND; MATERNAL CARE; MILK PRODUCTION; NATIONAL HEALTH ORGANIZATION; NONHUMAN; PREGNANCY LACTATION CYCLE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; PUERPERIUM; REVIEW; RISK REDUCTION; TERMINAL DUCT LOBULAR UNIT; TRANSLATIONAL RESEARCH; TRIPLE NEGATIVE BREAST CANCER; WAIST HIP RATIO;

ADULT; ANIMALS; BREAST; BREAST FEEDING; BREAST NEOPLASMS; CONGRESSES AS TOPIC; DISEASE MODELS, ANIMAL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INTERDISCIPLINARY COMMUNICATION; LACTATION; MILK, HUMAN; PARITY; POSTPARTUM PERIOD; PREGNANCY; PRIMARY PREVENTION; RISK FACTORS;

EID: 84873605440     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs505     Document Type: Review

References (90)

1. Sherman ME, Figueroa JD, Henry JE, et al. The Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center: a unique resource for defining the "molecular histology" of the breast. Cancer Prev Res (Phila). 2012;5(4):528-535.
2. Figueroa JD, Linville L, Brinton LA, et al. Breast cancer risk factor associations with breast tissue morphometry: results from the Komen for the Cure Tissue Bank. Paper presented at the American Association for Cancer Research Annual Meeting; April 2012; Chicago, IL.
3. Ip S, Chung M, Raman G, et al. Breastfeeding and maternal and infant health outcomes in developed countries. Evid Rep Technol Assess (Full Rep). 2007;XX(153):1-186.
4. Stuebe A. The risks of not breastfeeding for mothers and infants. Rev Obstet Gynecol. 2009;2(4):222-231.
5. Tse A, Michels KB. Maternal and offspring benefits of breast-feeding. In Symonds M, Ramsay MM eds. Maternal-Fetal Nutrition During Pregnancy and Lactation. Cambridge: Cambridge University Press; 2010:106-118.
6. Fielding J, Kumanyika S. Recommendations for the concepts and form of Healthy People 2020. Am J Prev Med. 2009;37(3):255-257.
7. Bernier MO, Plu-Bureau G, Bossard N, et al. Breastfeeding and risk of breast cancer: a metaanalysis of published studies. Hum Reprod Update. 2000;6(4):374-386.
8. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360(9328): 187-195.
9. Michels KB, Willett WC, Rosner BA, et al. Prospective assessment of breastfeeding and breast cancer incidence among 89,887 women. Lancet. 1996;347(8999):431-436.
10. Althuis MD, Fergenbaum JH, Garcia-Closas M, et al. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004;13(10):1558-1568.
11. Ma H, Bernstein L, Pike MC, et al. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a metaanalysis of epidemiological studies. Breast Cancer Res. 2006;8(4):R43.
12. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250-263.
13. Brinton LA, Sherman ME, Carreon JD, et al. Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst. 2008;100(22):1643-1648.
14. Anderson WF, Jatoi I, Sherman ME. Qualitative age interactions in breast cancer studies: mind the gap. J Clin Oncol. 2009;27(32):5308-5311.
15. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109(1):123-139.
16. Palmer JR, Boggs DA, Wise LA, et al. Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. Cancer Epidemiol Biomarkers Prev. 2011;20(9):1883-1891.
17. Gaudet MM, Press MF, Haile RW, et al. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat. 2011;130(2):587-597.
18. Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011;103(6):470-477.
19. Kotsopoulos J, Lubinski J, Salmena L, et al. Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2012;14(2):R42.
20. Stuebe AM, Willett WC, Xue F, et al. Lactation and incidence of premenopausal breast cancer: a longitudinal study. Arch Intern Med. 2009;169(15):1364-1571.
21. Milanese TR, Hartmann LC, Sellers TA, et al. Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst. 2006;98(22):1600-1607.
22. Yang XR, Figueroa JD, Falk RT, et al. Analysis of terminal duct lobular unit involution in luminal A and basal breast cancers. Breast Cancer Res. 2012;14(2):R64.
23. Cummings P, Weiss NS, McKnight B, et al. Estimating the risk of breast cancer in relation to the interval since last term pregnancy. Epidemiology. 1997;8(5):488-494.
24. Thompson WD. Age at and time since: modeling temporal aspects of exposure. Epidemiology. 1997;8(5):471-473.
25. Anderson WF, Matsuno RK, Sherman ME, et al. Estimating age-specific breast cancer risks: a descriptive tool to identify age interactions. Cancer Causes Control. 2007;18(4):439-447.
26. Zeleniuch-Jacquotte A, Afanasyeva Y, Kaaks R, et al. Premenopausal serum androgens and breast cancer risk: a nested case-control study. Breast Cancer Res. 2012;14(1):R32.
27. Hankinson SE, Eliassen AH. Circulating sex steroids and breast cancer risk in premenopausal women. Horm Cancer. 2010;1(1):2-10.
28. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94(8):606-616.
29. Tworoger SS, Eliassen AH, Sluss P, et al. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol. 2007;25(12):1482-1488.
30. Toriola AT, Vaarasmaki M, Lehtinen M, et al. Determinants of maternal sex steroids during the first half of pregnancy. Obstet Gynecol. 2011;118(5):1029-1036.
31. Troisi R, Hoover RN, Thadhani R, et al. Maternal, prenatal and perinatal characteristics and first trimester maternal serum hormone concentrations. Br J Cancer. 2008;99(7):1161-1164.
32. Eliassen AH, Tworoger SS, Hankinson SE. Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women. Int J Cancer. 2007;120(7):1536-1541.
33. Faupel-Badger JM, Sherman ME, Garcia-Closas M, et al. Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre-and postmenopausal women in a population-based case-control study from Poland. Br J Cancer. 2010;103(7):1097-1102.
34. Nagata C, Wada K, Nakamura K, et al. Associations of body size and reproductive factors with circulating levels of sex hormones and prolactin in premenopausal Japanese women. Cancer Causes Control. 2011;22(4):581-588.
35. Endogenous Hormones and Breast Cancer Collaborative Group, Key TJ, Appleby PN, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer. 2011;105(5):709-722.
36. Campino C, Torres C, Rioseco A, et al. Plasma prolactin/oestradiol ratio at 38 weeks gestation predicts the duration of lactational amenorrhoea. Hum Reprod. 2001;16(12):2540-2545.
37. Carlsen SM, Jacobsen G, Vanky E. Mid-pregnancy androgen levels are negatively associated with breastfeeding. Acta Obstet Gynecol Scand. 2010;89(1):87-94.
38. Stuebe AM, Bonuck K. What predicts intent to breastfeed exclusively? Breastfeeding knowledge, attitudes, and beliefs in a diverse urban population. Breastfeed Med. 2011;6(6):413-420.
39. Philipp BL, Merewood A. The baby-friendly way: the best breastfeeding start. Pediatr Clin North Am. 2004;51(3):761-783, xi.
40. Murtagh L, Moulton AD. Working mothers, breastfeeding, and the law. Am J Public Health. 2011;101(2):217-223.
41. Merrill RM, Fugal S, Novilla LB, et al. Cancer risk associated with early and late maternal age at first birth. Gynecol Oncol. 2005;96(3):583-593.
42. Ing R, Petrakis NL, Ho JH. Unilateral breast-feeding and breast cancer. Lancet. 1977;2(8029):124-127.
43. Garofalo R. Cytokines in human milk. J Pediatr. 2010;156(2 Suppl):S36-S40.
44. Tomicic S, Johansson G, Voor T, et al. Breast milk cytokine and IgA composition differ in Estonian and Swedish mothers-relationship to microbial pressure and infant allergy. Pediatr Res. 2010;68(4):330-334.
45. Dvorak B, Fituch CC, Williams CS, et al. Increased epidermal growth factor levels in human milk of mothers with extremely premature infants. Pediatr Res. 2003;54(1):15-19.
46. Castellote C, Casillas R, Ramirez-Santana C, et al. Premature delivery influences the immunological composition of colostrum and transitional and mature human milk. J Nutr. 2011;141(6):1181-1187.
47. Ustundag B, Yilmaz E, Dogan Y, et al. Levels of cytokines (IL-1beta, IL-2, IL-6, IL-8, TNF-alpha) and trace elements (Zn, Cu) in breast milk from mothers of preterm and term infants. Mediators Inflamm. 2005;2005(6):331-336.
48. Kverka M, Burianova J, Lodinova-Zadnikova R, et al. Cytokine profiling in human colostrum and milk by protein array. Clin Chem. 2007;53(5):955-962.
49. Innes KE, Byers TE. First pregnancy characteristics and subsequent breast cancer risk among young women. Int J Cancer. 2004;112(2):306-311.
50. Melbye M, Wohlfahrt J, Andersen AM, et al. Preterm delivery and risk of breast cancer. Br J Cancer. 1999;80(3-4):609-613.
51. Eccles SA. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol. 2011;55(7-9):685-696.
52. Zivkovic AM, German JB, Lebrilla CB, et al. Human milk glycobiome and its impact on the infant gastrointestinal microbiota. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4653-4658.
53. An HJ, Miyamoto S, Lancaster KS, et al. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res. 2006;5(7):1626-1635.
54. Kirmiz C, Li B, An HJ, et al. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics. 2007;6(1):43-55.
55. Leiserowitz GS, Lebrilla C, Miyamoto S, et al. Glycomics analysis of serum: a potential new biomarker for ovarian cancer? Int J Gynecol Cancer. 2008;18(3):470-475.
56. Li B, An HJ, Kirmiz C, et al. Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins. J Proteome Res. 2008;7(9):3776-3788.
57. Ruhaak LR, Miyamoto S, Kelly K, et al. N-glycan profiling of dried blood spots. Anal Chem. 2012;84(1):396-402.
58. Cregan MD, Fan Y, Appelbee A, et al. Identification of nestin-positive putative mammary stem cells in human breastmilk. Cell Tissue Res. 2007;329(1):129-136.
59. Hassiotou F, Beltran A, Chetwynd E, et al. Breastmilk is a novel source of stem cells with multi-lineage differentiation potential. Stem Cells. 2012;30(10):2164-2174.
60. Wong CM, Anderton DL, Smith-Schneider S, et al. Quantitative analysis of promoter methylation in exfoliated epithelial cells isolated from breast milk of healthy women. Epigenetics. 2010;5(7):645-655.
61. Thompson PA, Kadlubar FF, Vena SM, et al. Exfoliated ductal epithelial cells in human breast milk: a source of target tissue DNA for molecular epidemiologic studies of breast cancer. Cancer Epidemiol Biomarkers Prev. 1998;7(1):37-42.
62. Ambrosone CB, Abrams SM, Gorlewska-Roberts K, et al. Hair dye use, meat intake, and tobacco exposure and presence of carcinogen-DNA adducts in exfoliated breast ductal epithelial cells. Arch Biochem Biophys. 2007;464(2):169-175.
63. Browne EP, Punska EC, Lenington S, et al. Increased promoter methylation in exfoliated breast epithelial cells in women with a previous breast biopsy. Epigenetics. 2011;6(12):1425-1435.
64. Browne EP, Punska EC, Anderton DL, Lenington S, Arcaro KF. Methylation in exfoliated epithelial cells from lactating women at increased risk for developing breast cancer. Paper presented at Annual Conference American Association for Cancer Research; April 2-6, 2011; Orlando, FL.
65. Becker GE, Cooney F, Smith HA. Methods of milk expression for lactating women. Cochrane Database Syst Rev. 2011;12:CD006170.
66. Mitoulas LR, Kent JC, Cox DB, et al. Variation in fat, lactose and protein in human milk over 24 h and throughout the first year of lactation. Br J Nutr. 2002;88(1):29-37.
67. Kent JC, Mitoulas LR, Cregan MD, et al. Volume and frequency of breastfeedings and fat content of breast milk throughout the day. Pediatrics. 2006;117(3):e387-e395.
68. Hassiotou F, Hepworth A, Trengrove N, Lai CT, Hartmann PE. Coordinated response of the fat and cellular content of breastmilk to the degree of fullness of the breast. Paper presented at Experimental Biology; April 19-25, 2012; San Diego, CA.
69. Humphreys RC, Bierie B, Zhao L, et al. Deletion of Stat3 blocks mammary gland involution and extends functional competence of the secretory epithelium in the absence of lactogenic stimuli. Endocrinology. 2002; 143(9):3641-3650.
70. Hughes K, Wickenden JA, Allen JE, et al. Conditional deletion of Stat3 in mammary epithelium impairs the acute phase response and modulates immune cell numbers during post-lactational regression. J Pathol. 2012;227(1): 106-117.
71. Kreuzaler PA, Staniszewska AD, Li W, et al. Stat3 controls lysosomalmediated cell death in vivo. Nat Cell Biol. 2011;13(3):303-309.
72. Watson CJ, Kreuzaler PA. Remodeling mechanisms of the mammary gland during involution. Int J Dev Biol. 2011;55(7-9):757-762.
73. Watson, CJ. Involution: apoptosis and tissue remodelling that convert the mammary gland from milk factory to a quiescent organ. Breast Cancer Res. 2006;8(2):203-207.
74. Hennighausen L, Robinson GW. Signaling pathways in mammary gland development. Dev Cell. 2001;1(4):467-475.
75. Lyons TR, O'Brien J, Borges VF, et al. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med. 2011;17(9):1109-1115.
76. Maller O, Martinson H, Schedin P. Extracellular matrix composition reveals complex and dynamic stromal-epithelial interactions in the mammary gland. J Mammary Gland Biol Neoplasia. 2010;15(3):301-318.
77. Schedin PJ, Thackray LB, Malone P, et al. Programmed cell death and mammary neoplasia. Cancer Treat Res. 1996;83:3-22.
78. Bemis LT, Schedin P. Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion. Cancer Res. 2000;60(13):3414-3418.
79. Schedin P, Strange R, Mitrenga T, et al. Fibronectin fragments induce MMP activity in mouse mammary epithelial cells: evidence for a role in mammary tissue remodeling. J Cell Sci. 2000;113(Pt 5):795-806.
80. Schedin P, Mitrenga T, McDaniel S, et al. Mammary ECM composition and function are altered by reproductive state. Mol Carcinog. 2004;41(4):207-220.
81. McDaniel SM, Rumer KK, Biroc SL, et al. Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am J Pathol. 2006;168(2):608-620.
82. Stein T, Morris JS, Davies CR, et al. Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Res. 2004;6(2):R75-R91.
83. Clarkson RW, Wayland MT, Lee J, et al. Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. Breast Cancer Res. 2004;6(2):R92-R109.
84. O'Brien J, Lyons T, Monks J, et al. Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am J Pathol. 2010;176(3):1241-1255.
85. Bladstrom A, Anderson H, Olsson H. Worse survival in breast cancer among women with recent childbirth: results from a Swedish populationbased register study. Clin Breast Cancer. 2003;4(4):280-285.
86. Johansson AL, Andersson TM, Hsieh CC, et al. Increased mortality in women with breast cancer detected during pregnancy and different periods postpartum. Cancer Epidemiol Biomarkers Prev. 2011;20(9):1865-1872.
87. Stensheim H, Moller B, van Dijk T, et al. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registrybased cohort study. J Clin Oncol. 2009;27(1):45-51.
88. Schedin P. Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer. 2006;6(4):281-291.
89. Holmes MD, Chen WY, Li L, et al. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28(9):1467-1472.
90. Tiede B, Kang Y. From milk to malignancy: the role of mammary stem cells in development, pregnancy and breast cancer. Cell Res. 2011;21(2):245-257.